Related Experiment Videos
Concomitant occurrence of disseminated intravascular coagulation and factor VIII inhibitor in a patient with
Insights
A prostate cancer patient developed disseminated intravascular coagulation (DIC) and a rare acquired factor VIII inhibitor. This previously unreported co-occurrence highlights complex bleeding risks in advanced cancer patients.
Area of Science:
- Hematology
- Oncology
- Internal Medicine
Background:
- Advanced prostate cancer (Stage D) presents complex clinical challenges.
- Disseminated intravascular coagulation (DIC) is a critical bleeding complication.
- Acquired factor VIII inhibitors are rare autoimmune disorders affecting coagulation.
Observation:
- An 86-year-old male with Stage D prostate cancer experienced spontaneous bleeding from multiple sites.
- Laboratory results confirmed disseminated intravascular coagulation (DIC).
- A significant level (12.5 Bethesda units) of acquired factor VIII inhibitor was detected in his plasma.
Findings:
- The patient presented with a simultaneous diagnosis of disseminated intravascular coagulation (DIC) and an acquired factor VIII inhibitor.
- This represents the first reported case of this specific co-occurrence in medical literature.
- The presence of the factor VIII inhibitor likely contributed to the severe bleeding manifestations.
Implications:
- This case suggests a potential link between advanced malignancy and the development of acquired factor VIII inhibitors.
- Understanding this association may improve diagnostic and therapeutic strategies for bleeding complications in cancer patients.
- Further research is warranted to explore the mechanisms underlying this rare comorbidity.
Abstract:
An 86-year-old man, diagnosed as having carcinoma of the prostate, stage D, was admitted to the hospital. Soon after admission, he developed bleeding from various sites, including intravenous puncture sites and gastrointestinal and urinary tracts. A clinical diagnosis of disseminated intravascular coagulation (DIC) was made, which was corroborated by laboratory data. A factor VIII inhibitor of 12.5 Bethesda units was also identified in the patient's plasma. Concomitant occurrence of disseminated intravascular coagulation and an acquired factor VIII inhibitor has not been reported previously.